18 Commerce Way
Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune intends to progress these rapidly through clinical trials and to combine these with checkpoint blockade at an early stage of clinical development.
Executive Chairman & Director: Philip Astley-Sparke
CEO & Director: Robert Coffin, Ph.D.
COO: Colin Love, Ph.D.
CBO: Pamela Esposito, Ph.D.
CMO: Howard Kaufman, M.D.
VP, Clinical Development: Susan Doleman
Sr. VP of Regulatory Affairs and QA: Anne Marie Woodland
VP, Research: Suzanne Thomas, Ph.D.
Please click here for Replimune's science.
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.